CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

Three ways you can design better drug trials for schizophrenia therapeutics

To date, no effective drugs have been developed to address cognitive dysfunction in schizophrenia. Here we will highlight the three main methodological challenges which may be contributing to these high failure rates, and propose potential practical solutions to these problems.                                                                                                                                                                                                  

CANTAB Research Grant funds investigation of chronic inflammation in depression

PhD Student Naoise Mac Giollabhui received a CANTAB Research Grant in 2018 for his project: ‘Chronic inflammation as a pathway to cognitive dysfunction in adolescents and young adults with a history of elevated depressive symptoms’. We caught up with Naoise to discuss how the grant will benefit his research. 

Revolutionising the detection of cognitive impairment in patients with multiple sclerosis

Cognitive dysfunction is a leading cause of disability in multiple sclerosis (MS), yet practical restraints mean it often goes unassessed in routine clinical care. Promising new research, published in Frontiers in Neurology, suggests the Cambridge Neuropsychological Test Automated Battery (CANTAB) may offer a brief and sensitive technological solution.

Join us at SIRS 2018

Cambridge Cognition are attending the Schizophrenia International Research Society Conference (SIRS): 4th - 8th April 2018

Can acetylcholinesterase inhibitors and CNS stimulants tackle cognitive dysfunction in multiple scle

Cognitive dysfunction in multiple sclerosis (MS) presents a significant, unmet therapeutic need. Researchers at Cambridge Cognition and the University of Manchester investigated potential solutions to this problem with a systematic review and meta-analysis of pro-cognitive drug trials in MS. 

web-based testing, wearables, voice recognition, virtual research, virtual clinical trials, technology, swm, subjective measures, stigma, social cognition, soc, smartphones, schizophrenia research, schizophrenia, research funding, remote testing, regulations, recruitment, real-world assessments, prodromal, pro-cognitive, presenteeism, preclinical, precision psychiatry, pre-clinical, physical health, personalised medicine, patient-centric, patient recruitment, patient finding, parkinson's disease, pal, ots, opinion piece, occupational health, objective measures, normative data, neurotech, neuroscience, near-patient testing, multiple sclerosis, ms, modelling, modafinil, mental wellbeing, mental health, mci, major depression, lifespan, innovate uk, ied, icosr, high frequency, healthcare, ert, epidemiology, emotion recognition, ecological momentary assessments, ebt, ebbinghaus, early alzheimer's disease, drug development, digital tools, digital health, diagnosis, depression, dementia, computerised testing, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, cias, chronic pain, cgt, cantab research grant, cantab for clinical trials, cantab, brain health, brain donor program, biomarkers, awards, automatic speech recognition, autism, attention, at-home testing, asd, alzheimer's disease, affective cognition, absenteeism,